miR-325 serves as a prognostic biomarker and regulates tumor progression by targeting ARRDC3 in ovarian cancer

Ovarian cancer (OC) has a poor prognosis and lacks precise biomarkers and therapeutic targets. The tumor-suppressing effects of miR-325 and ARRDC3 have been demonstrated in multiple cancer types, but their association and mechanisms in OC remain unclear. Investigate the prognostic value of miR-325 in OC, clarify its regulatory relationship with ARRDC3, and elucidate its mechanism of action in tumor progression. Detect the expression of miR-325 and ARRDC3 in OC tissue, normal tissue, and A2780 and CAOV-3 cells, and analyze their association with pathological features and prognosis using clinical data. Assess malignant phenotypes, such as proliferation and apoptosis, through the intervention of miR-325 mimic/inhibitor in cells. Validate the direct binding relationship between the two using a dual luciferase reporter assay. miR-325 and ARRDC3 are markedly downregulated in OC tissues and cells, with a strong positive correlation between their expression levels in OC tissues. Low miR-325 expression correlates with poor tumor differentiation, advanced FIGO stage, lymph node metastasis, and a poor prognosis in patients, and serves as an independent prognostic factor. Overexpression of miR-325 inhibits OC cell proliferation and invasion. A dual luciferase assay confirms that miR-325 binds to the 3’UTR of ARRDC3, thereby suppressing its expression. miR-325 is downregulated in OC and holds prognostic value. Targeting ARRDC3 expression provides new evidence for OC prognosis assessment and molecular mechanism research.